Research article · 15 Apr 2026
Conference abstractPublished 14 May 2018
Evaluation of the absorbed dose to the kidneys due to Tc99m (DTPA)/Tc99m (Mag3) and Tc99m (Dmsa)
Universidad Nacional de Trujillo, Peru Instituto Nacional de Enfermedades Neoplasicas, Peru
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The estimated dose absorbed by the kidneys, during studies of renal function of adult patients can be done through the analysis of the bio-kinetics of radiopharmaceuticals used, which contain Tc99m (DTPA)/Tc99m (MAG3) or Tc99m (DMSA). The absorbed dose in the kidneys of adult patients has been assessed using the bio kinetics of radiopharmaceuticals containing Tc99m (DTPA)/Tc99m (Mag3) or Tc99m (Dmsa). The absorbed dose was calculated using the formalism MIRD and the Cristy-Eckerman representation for the kidneys. The absorbed dose to the kidneys due to Tc99m (DTPA)/Tc99m (Mag3), are given by 0.00466 mGy.MBq-1/0.00339 mGy.MBq-1. Approximately 21.2% of the absorbed dose is due to the bladder (content) and the remaining tissue, included in bio-kinetics of Tc99m (DTPA)/Tc99m (Mag3). The absorbed dose to the kidneys due to Tc99m (Dmsa) is 0.17881 mGy.MBq-1. Here, 1.7% of the absorbed dose is due to the bladder, spleen, liver and the remaining tissue, included in bio-kinetics of Tc99m (Dmsa). Using the MIRD methodology and the Cristy-Eckerman representation for kidneys of adult patients, it is shown that, during studies of renal function, the contributions dissymmetric organs, which are part of the bio kinetics (excluding the kidneys) of Tc99m (DPTA)/Tc-99m (DMSA), and Tc-99m (MAG3), are very significant in the estimated dose absorbed by the patient.
Subjects
Nephrology & UrologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Nephrology & Therapeutics.
Brief report · 30 Mar 2026
Renal Fibrosis: Targeting Pathways For New Therapies
Brief report · 30 Mar 2026
SGLT2 Inhibitors: A New Era for Diabetic Kidney Disease
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Nephrology & Therapeutics
- SubjectNephrology & Urology
- BylineArticles whose byline prints “Vasquez Arteaga Marcial”
- BylineArticles whose byline prints “Castillo Diestra Carlos”
- BylineArticles whose byline prints “Rocha Jara Jorge”
- BylineArticles whose byline prints “Sifuentes Diaz Yenny”
- BylineArticles whose byline prints “Sanchez Sandova Paulino”
- BylineArticles whose byline prints “Marquez Pachas Fernando”
